Effects of Psilocybin in Post-Treatment Lyme Disease

This pilot, open-label trial will evaluate the effects of two psilocybin sessions (session 1: 15 mg; session 2: 15 mg or 25 mg) delivered with psychological support over an 8-week course in 20 participants with Post-Treatment Lyme Disease (PTLD).

Outcomes include change in overall symptom burden and quality of life with follow-up assessments at 1, 3, and 6 months; safety screening includes ECG, labs, and psychiatric assessment. Concurrent stable SSRIs/SNRIs or bupropion (≤300 mg/day) are permitted.